Moreover, while the patient base for Duchenne may be too small to spark a billion-dollar drug, the PTC chemical could work against similar underlying gene flaws in other disorders such as cystic fibrosis, hemophilia and spinal muscular atrophy.

FORBES: Stopping the Nonsense